Literature DB >> 18941190

Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype.

Cyril Fauriat1, Sandra Andersson, Andreas T Björklund, Mattias Carlsten, Marie Schaffer, Niklas K Björkström, Bettina C Baumann, Jakob Michaëlsson, Hans-Gustaf Ljunggren, Karl-Johan Malmberg.   

Abstract

Stem cell transplantation across HLA barriers may trigger NK cell-mediated graft-vs-leukemia effects leading to improved survival for patients with hematological malignancies. However, the genetic algorithm based on killer cell Ig-like receptor (KIR) and HLA genes used to predict NK cell alloreactivity have yielded discrepant results. Accordingly, it has been difficult to define transplantation settings that favor NK cell alloreactivity. In this study, we have used multiparameter flow cytometry to simultaneously analyze the cell surface expression of all four major inhibitory KIR and CD94/NKG2A to determine the size of the alloreactive NK cell repertoires in 31 individuals homozygous for the group A KIR haplotype. We observed a vast variability in the frequencies of cells with an alloreactive potential, ranging from 0 to 62% of the total NK cell population depending on which, and how many, KIR ligands were missing in theoretical recipients. This analysis required a functional examination of KIR3DL2-single positive NK cells, showing that this subset was hyporesponsive in individuals harboring the cognate ligands HLA-A3/A11. The results provide new insights into the variability of the functional alloreactive NK cell repertoire and have implications for donor selection in hematopoietic stem cell transplantation and adoptive NK cell-based immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941190     DOI: 10.4049/jimmunol.181.9.6010

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

Review 1.  Current perspectives of natural killer cell education by MHC class I molecules.

Authors:  Petter Höglund; Petter Brodin
Journal:  Nat Rev Immunol       Date:  2010-09-06       Impact factor: 53.106

Review 2.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

3.  NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation.

Authors:  Andreas T Björklund; Marie Schaffer; Cyril Fauriat; Olle Ringdén; Mats Remberger; Christina Hammarstedt; A John Barrett; Per Ljungman; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2010-01-22       Impact factor: 22.113

4.  NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Julie Curtsinger; Xianghua Luo; Edmund K Waller; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Blood       Date:  2011-07-14       Impact factor: 22.113

5.  CD8 T cells express randomly selected KIRs with distinct specificities compared with NK cells.

Authors:  Niklas K Björkström; Vivien Béziat; Frank Cichocki; Lisa L Liu; Jeffrey Levine; Stella Larsson; Richard A Koup; Stephen K Anderson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

6.  HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors.

Authors:  Jodie P Goodridge; Aura Burian; Ni Lee; Daniel E Geraghty
Journal:  J Immunol       Date:  2013-09-09       Impact factor: 5.422

7.  CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Authors:  Juan Du; Sandra Lopez-Verges; Brandelyn N Pitcher; Jeffrey Johnson; Sin-Ho Jung; Lili Zhou; Katharine Hsu; Myron S Czuczman; Bruce Cheson; Lawrence Kaplan; Lewis L Lanier; Jeffrey M Venstrom
Journal:  Cancer Immunol Res       Date:  2014-06-23       Impact factor: 11.151

8.  The D0 Ig-like domain plays a central role in the stronger binding of KIR3DL2 to B27 free H chain dimers.

Authors:  Hiroko Hatano; Jacqueline Shaw; Kaitlin Marquardt; Zhiyong Zhang; Laurent Gauthier; Stephanie Chanteux; Benjamin Rossi; Demin Li; Julie Mitchell; Simon Kollnberger
Journal:  J Immunol       Date:  2015-01-12       Impact factor: 5.422

9.  Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands.

Authors:  Ketevan Gendzekhadze; Paul J Norman; Laurent Abi-Rached; Thorsten Graef; Achim K Moesta; Zulay Layrisse; Peter Parham
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-16       Impact factor: 11.205

Review 10.  Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR).

Authors:  Amanda K Purdy; Kerry S Campbell
Journal:  Cancer Biol Ther       Date:  2009-12-28       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.